Product/Composition:- | Carvedilol tablet/Capsules |
---|---|
Strength:- | 3.125 mg, 6.25 mg, 12.5 mg, 25 mg |
Form:- | Tablet/Capsules |
Reference Brands:- | Coreg(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Carvedilol is a non-selective beta-blocker with alpha-1 blocking activity, which reduces heart rate, blood pressure, and myocardial oxygen demand. It improves cardiac output and decreases sympathetic nervous system activity. Benefits include controlling hypertension, managing heart failure, reducing post-MI mortality, and improving overall cardiovascular health and survival outcomes.
Carvedilol tablets are approved in the US by the FDA and in the EU via EMA for treating hypertension, heart failure, and post-myocardial infarction. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, the FDA reviews detailed clinical trial and manufacturing data, while the EMA ensures regional safety and quality compliance. For guidance on dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and global availability of carvedilol tablets, helping improve cardiovascular outcomes and patients’ quality of life worldwide.